Results 51 to 60 of about 23,125,138 (369)
mAbs, 2021 Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα.
Inja Waldhauer +28 more
doaj +1 more source
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source
Structure-function relationships for the interleukin 2 receptor system
Memorias do Instituto Oswaldo Cruz, 1987 Receptors for interleukin 2 (IL-2) esit in at least three forms which differ in their subunit compositio, their affinity for ligand and their ability to mediate a cellular reponse.
Richard J. Robb
doaj +1 more source
A versatile design platform for glycoengineering therapeutic antibodies
mAbs, 2022 Manipulation of glycosylation patterns, i.e., glycoengineering, is incorporated in the therapeutic antibody development workflow to ensure clinical safety, and this approach has also been used to modulate the biological activities, functions, or ...
Seth D. Ludwig +9 more
doaj +1 more source
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source
Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals [PDF]
, 2014 Despite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic ...
Finocchiaro, Liliana Maria Elena +1 more
core +4 more sources
Journal of Blood Medicine, 2021 Tamar A Smith-Norowitz, Sarah Shidid, Yitzchok M Norowitz, Stephan Kohlhoff Department of Pediatrics, Division of Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, NY, 11203, USACorrespondence: Tamar A Smith ...
Smith-Norowitz TA +3 more
doaj
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system [PDF]
, 2006 We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the
Pitzer, Claudia +4 more
core